ChabioTech Signs Contract for Cell Therapy Contract Manufacturing with SCM Life Sciences
SCM Life Sciences Plans Production of SCM-AGH and SCM-CGH Under Development
[Asia Economy Reporter Kim Ji-hee] Cha Biotech announced on the 23rd that it has signed a contract for the contract manufacturing organization (CMO) of bone marrow-derived cell therapy finished products with SCM Life Sciences, a cell therapy development company.
Through this contract, Cha Biotech will produce the ‘SCM-AGH’ and ‘SCM-CGH’ products developed by SCM Life Sciences through its subsidiary Cha Biolab’s pharmaceutical manufacturing facility. Additionally, there is a high possibility of expanding production to commercial products to be launched in the future.
The products in question are for chronic graft-versus-host disease (SCM-CGH), currently in phase 2 clinical trials, and acute pancreatitis (SCM-AGH), currently in phase 2a clinical trials. According to Cha Biotech, these therapies have been designated as orphan drugs in the development stage by the Ministry of Food and Drug Safety, and conditional product approval is likely after the completion of phase 2 clinical trials. SCM Life Sciences also plans to utilize the know-how of operating cGMP production facilities of CoImmune in the United States.
Lee Byung-geon, CEO of SCM Life Sciences, said, “Although we have our own GMP facility licensed for advanced biopharmaceutical manufacturing, we hope to complete the ongoing clinical trials and expedite product launch through conditional approval by collaborating with Cha Biotech,” adding, “Based on Cha Biotech’s expertise in stem cell therapy development and GMP production facility operation capabilities, we will be able to produce high-quality products.”
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Samsung Electronics Labor-Management Agreement, Nvidia Revenue Surges... KOSPI Soars Over 6%
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Oh Sang-hoon, CEO of Cha Biotech, emphasized, “With this contract as a milestone, we plan to expand strategic cooperation with SCM Life Sciences throughout the entire process from stem cell therapy clinical trials to product manufacturing,” and “We will actively support SCM Life Sciences’ cell therapy development by leveraging Cha Biotech’s capabilities and the industry-academia-research-hospital system possessed by the Cha Biotech Group.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
